# OnCo record orum-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/orum-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "orum-therapeutics" ;
  schema:name "Orum Therapeutics"@en ;
  schema:description "Orum Therapeutics attaches protein-destroying drugs to antibodies so they are delivered only into cancer cells. Its lead medicine for acute myeloid leukaemia is entering human trials, and the company is listed on the Korean stock market."@en ;
  schema:url <https://onco.cc/companies/orum-therapeutics/>, <https://www.orumrx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.orumrx.com/>, <https://www.orumrx.com/news/3zokvvtwmn7jjpn0uevjkivk30uvu4>, <https://www.orumrx.com/news/orum-therapeutics-announces-pricing-of-initial-public-offeringnbsp>, <https://www.orumrx.com/news/orum-therapeutics-secures-approximately-us100-million-to-accelerate-development-of-leading-degrader-antibody-conjugate-programs-to-treat-serious-diseases-251218>, <https://www.orumrx.com/news/orum-orm-6151-acquisition-by-bms> ;
  schema:addressCountry "KR" ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/degrader-antibody-conjugate/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/cd33/>, <https://onco.cc/targets/cd123/> .